WILMINGTON, DE — The Chemours Company (NYSE: CC) has released its financial results for the first quarter of 2025. The company reported net sales of $1.4 billion, consistent with the corresponding period last year, and underscored progress in strategic growth areas despite facing challenging market conditions.
Key financial metrics for Q1 include a net loss of $4 million, or $0.03 per diluted share, compared to net income of $54 million, or $0.36 per diluted share, in the first quarter of 2024. Adjusted EBITDA stood at $166 million, a decrease from $191 million in the prior-year quarter, driven by pricing pressures and macroeconomic headwinds.
“We made important progress against the key pillars of our Pathway to Thrive strategy,” said Denise Dignam, Chemours President and CEO. “While we experienced some headwinds across all three businesses, macroeconomic and business-related, we remain steadfast in executing our strategy, focusing on driving long-term shareholder value.”
The Thermal & Specialized Solutions (TSS) segment was a standout performer, with 40% year-over-year growth in Opteon™ Refrigerant sales fueled by strong demand and capacity expansion at the Corpus Christi facility. Similarly, Titanium Technologies (TT) and Advanced Performance Materials (APM) segments saw mixed performance, with TT delivering modest growth of 1% in net sales and APM facing a 3% decline largely due to weaker demand in hydrogen-related markets and currency fluctuations.
Strategic initiatives also advanced during the quarter, highlighted by a manufacturing agreement with Navin Fluorine International, Ltd. to produce two-phase immersion cooling fluid. Meanwhile, Chemours took steps to streamline its portfolio by exiting the Surface Protection Solutions (SPS) Capstone™ business, a decision influenced by regulatory and market challenges.
To improve financial flexibility, Chemours reduced its dividend by 65% to $0.0875 per share and amended its credit agreement, extending commitments to 2030 and reinforcing its liquidity profile.
Looking ahead, the company projects Q2 2025 net sales to grow in the low-to-mid teens sequentially, with adjusted EBITDA expected to increase by 40%-45%. For the full year, Chemours forecasts adjusted EBITDA between $825 million and $950 million, with capital expenditures ranging from $225 million to $275 million.
Despite short-term challenges, Chemours remains committed to executing its Pathway to Thrive strategy, driving innovation, and delivering shareholder value over the long term.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.